
Global Biologics and Biosimilars Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Biologics and Biosimilars market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Biologics and Biosimilars market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Biologics and Biosimilars market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Pfizer, AbbVie, United Laboratory and Tonghua Dongbao, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Biologics and Biosimilars, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biologics and Biosimilars, also provides the value of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics and Biosimilars revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Biologics and Biosimilars company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Biologics and Biosimilars Segment by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Pfizer
AbbVie
United Laboratory
Tonghua Dongbao
Sobi
Novo Nordisk
Kanghong Pharma
Innovent Biologics
Gan&Lee
Eli Lilly
Changchun High Tech
Celltrion
Biogen
Amgen
3SBIO
Biologics and Biosimilars Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Biologics and Biosimilars Segment by Application
Hospital
Retail Pharmacy
Other
Biologics and Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Biologics and Biosimilars status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Biologics and Biosimilars key companies, revenue, market share, and recent developments.
3. To split the Biologics and Biosimilars breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.
6. To analyze Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics and Biosimilars industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Biologics and Biosimilars market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Biologics and Biosimilars market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Biologics and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Biologics and Biosimilars market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Pfizer, AbbVie, United Laboratory and Tonghua Dongbao, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Biologics and Biosimilars, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Biologics and Biosimilars, also provides the value of main regions and countries. Of the upcoming market potential for Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biologics and Biosimilars revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Biologics and Biosimilars company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Biologics and Biosimilars Segment by Company
Sanofi
Johnson & Johnson
Novartis
Merck
Roche
Pfizer
AbbVie
United Laboratory
Tonghua Dongbao
Sobi
Novo Nordisk
Kanghong Pharma
Innovent Biologics
Gan&Lee
Eli Lilly
Changchun High Tech
Celltrion
Biogen
Amgen
3SBIO
Biologics and Biosimilars Segment by Type
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others
Biologics and Biosimilars Segment by Application
Hospital
Retail Pharmacy
Other
Biologics and Biosimilars Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Biologics and Biosimilars status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Biologics and Biosimilars key companies, revenue, market share, and recent developments.
3. To split the Biologics and Biosimilars breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.
6. To analyze Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics and Biosimilars industry.
Chapter 3: Detailed analysis of Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
203 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Biologics and Biosimilars Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Biologics and Biosimilars Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Biologics and Biosimilars Market Dynamics
- 2.1 Biologics and Biosimilars Industry Trends
- 2.2 Biologics and Biosimilars Industry Drivers
- 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
- 2.4 Biologics and Biosimilars Industry Restraints
- 3 Biologics and Biosimilars Market by Company
- 3.1 Global Biologics and Biosimilars Company Revenue Ranking in 2024
- 3.2 Global Biologics and Biosimilars Revenue by Company (2020-2025)
- 3.3 Global Biologics and Biosimilars Company Ranking (2023-2025)
- 3.4 Global Biologics and Biosimilars Company Manufacturing Base and Headquarters
- 3.5 Global Biologics and Biosimilars Company Product Type and Application
- 3.6 Global Biologics and Biosimilars Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Biologics and Biosimilars Market by Type
- 4.1 Biologics and Biosimilars Type Introduction
- 4.1.1 Monoclonal Antibodies
- 4.1.2 Interferon
- 4.1.3 Insulin
- 4.1.4 Vaccines
- 4.1.5 Others
- 4.2 Global Biologics and Biosimilars Sales Value by Type
- 4.2.1 Global Biologics and Biosimilars Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Biologics and Biosimilars Sales Value by Type (2020-2031)
- 4.2.3 Global Biologics and Biosimilars Sales Value Share by Type (2020-2031)
- 5 Biologics and Biosimilars Market by Application
- 5.1 Biologics and Biosimilars Application Introduction
- 5.1.1 Hospital
- 5.1.2 Retail Pharmacy
- 5.1.3 Other
- 5.2 Global Biologics and Biosimilars Sales Value by Application
- 5.2.1 Global Biologics and Biosimilars Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Biologics and Biosimilars Sales Value by Application (2020-2031)
- 5.2.3 Global Biologics and Biosimilars Sales Value Share by Application (2020-2031)
- 6 Biologics and Biosimilars Regional Value Analysis
- 6.1 Global Biologics and Biosimilars Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Biologics and Biosimilars Sales Value by Region (2020-2031)
- 6.2.1 Global Biologics and Biosimilars Sales Value by Region: 2020-2025
- 6.2.2 Global Biologics and Biosimilars Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Biologics and Biosimilars Sales Value (2020-2031)
- 6.3.2 North America Biologics and Biosimilars Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Biologics and Biosimilars Sales Value (2020-2031)
- 6.4.2 Europe Biologics and Biosimilars Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Biologics and Biosimilars Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Biologics and Biosimilars Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Biologics and Biosimilars Sales Value (2020-2031)
- 6.6.2 South America Biologics and Biosimilars Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Biologics and Biosimilars Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Biologics and Biosimilars Sales Value Share by Country, 2024 VS 2031
- 7 Biologics and Biosimilars Country-level Value Analysis
- 7.1 Global Biologics and Biosimilars Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Biologics and Biosimilars Sales Value by Country (2020-2031)
- 7.2.1 Global Biologics and Biosimilars Sales Value by Country (2020-2025)
- 7.2.2 Global Biologics and Biosimilars Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.7.2 France Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.14.2 China Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.17.2 India Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Biologics and Biosimilars Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Biologics and Biosimilars Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Biologics and Biosimilars Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Sanofi
- 8.1.1 Sanofi Comapny Information
- 8.1.2 Sanofi Business Overview
- 8.1.3 Sanofi Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.1.4 Sanofi Biologics and Biosimilars Product Portfolio
- 8.1.5 Sanofi Recent Developments
- 8.2 Johnson & Johnson
- 8.2.1 Johnson & Johnson Comapny Information
- 8.2.2 Johnson & Johnson Business Overview
- 8.2.3 Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.2.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
- 8.2.5 Johnson & Johnson Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Comapny Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.3.4 Novartis Biologics and Biosimilars Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Merck
- 8.4.1 Merck Comapny Information
- 8.4.2 Merck Business Overview
- 8.4.3 Merck Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.4.4 Merck Biologics and Biosimilars Product Portfolio
- 8.4.5 Merck Recent Developments
- 8.5 Roche
- 8.5.1 Roche Comapny Information
- 8.5.2 Roche Business Overview
- 8.5.3 Roche Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.5.4 Roche Biologics and Biosimilars Product Portfolio
- 8.5.5 Roche Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Comapny Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.6.4 Pfizer Biologics and Biosimilars Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 AbbVie
- 8.7.1 AbbVie Comapny Information
- 8.7.2 AbbVie Business Overview
- 8.7.3 AbbVie Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.7.4 AbbVie Biologics and Biosimilars Product Portfolio
- 8.7.5 AbbVie Recent Developments
- 8.8 United Laboratory
- 8.8.1 United Laboratory Comapny Information
- 8.8.2 United Laboratory Business Overview
- 8.8.3 United Laboratory Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.8.4 United Laboratory Biologics and Biosimilars Product Portfolio
- 8.8.5 United Laboratory Recent Developments
- 8.9 Tonghua Dongbao
- 8.9.1 Tonghua Dongbao Comapny Information
- 8.9.2 Tonghua Dongbao Business Overview
- 8.9.3 Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.9.4 Tonghua Dongbao Biologics and Biosimilars Product Portfolio
- 8.9.5 Tonghua Dongbao Recent Developments
- 8.10 Sobi
- 8.10.1 Sobi Comapny Information
- 8.10.2 Sobi Business Overview
- 8.10.3 Sobi Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.10.4 Sobi Biologics and Biosimilars Product Portfolio
- 8.10.5 Sobi Recent Developments
- 8.11 Novo Nordisk
- 8.11.1 Novo Nordisk Comapny Information
- 8.11.2 Novo Nordisk Business Overview
- 8.11.3 Novo Nordisk Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.11.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
- 8.11.5 Novo Nordisk Recent Developments
- 8.12 Kanghong Pharma
- 8.12.1 Kanghong Pharma Comapny Information
- 8.12.2 Kanghong Pharma Business Overview
- 8.12.3 Kanghong Pharma Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.12.4 Kanghong Pharma Biologics and Biosimilars Product Portfolio
- 8.12.5 Kanghong Pharma Recent Developments
- 8.13 Innovent Biologics
- 8.13.1 Innovent Biologics Comapny Information
- 8.13.2 Innovent Biologics Business Overview
- 8.13.3 Innovent Biologics Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.13.4 Innovent Biologics Biologics and Biosimilars Product Portfolio
- 8.13.5 Innovent Biologics Recent Developments
- 8.14 Gan&Lee
- 8.14.1 Gan&Lee Comapny Information
- 8.14.2 Gan&Lee Business Overview
- 8.14.3 Gan&Lee Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.14.4 Gan&Lee Biologics and Biosimilars Product Portfolio
- 8.14.5 Gan&Lee Recent Developments
- 8.15 Eli Lilly
- 8.15.1 Eli Lilly Comapny Information
- 8.15.2 Eli Lilly Business Overview
- 8.15.3 Eli Lilly Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.15.4 Eli Lilly Biologics and Biosimilars Product Portfolio
- 8.15.5 Eli Lilly Recent Developments
- 8.16 Changchun High Tech
- 8.16.1 Changchun High Tech Comapny Information
- 8.16.2 Changchun High Tech Business Overview
- 8.16.3 Changchun High Tech Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.16.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
- 8.16.5 Changchun High Tech Recent Developments
- 8.17 Celltrion
- 8.17.1 Celltrion Comapny Information
- 8.17.2 Celltrion Business Overview
- 8.17.3 Celltrion Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.17.4 Celltrion Biologics and Biosimilars Product Portfolio
- 8.17.5 Celltrion Recent Developments
- 8.18 Biogen
- 8.18.1 Biogen Comapny Information
- 8.18.2 Biogen Business Overview
- 8.18.3 Biogen Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.18.4 Biogen Biologics and Biosimilars Product Portfolio
- 8.18.5 Biogen Recent Developments
- 8.19 Amgen
- 8.19.1 Amgen Comapny Information
- 8.19.2 Amgen Business Overview
- 8.19.3 Amgen Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.19.4 Amgen Biologics and Biosimilars Product Portfolio
- 8.19.5 Amgen Recent Developments
- 8.20 3SBIO
- 8.20.1 3SBIO Comapny Information
- 8.20.2 3SBIO Business Overview
- 8.20.3 3SBIO Biologics and Biosimilars Revenue and Gross Margin (2020-2025)
- 8.20.4 3SBIO Biologics and Biosimilars Product Portfolio
- 8.20.5 3SBIO Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.